UNSPSC 51201818: Roquinimex

This classification denotes an immunostimulant and angiogenesis activator inhibitor with the molecular formula C18H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 372T2944C0, chemically known as 1,2-dihydro-4-hydroxy-n,1-dimethyl-2-oxo-3-quinolinecarboxanilide but generally known as roquinimex, which bears US NIH Compound Identifier 55197. European Medicines Agency schedules Roquinimex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10384MIG.

UNSPSC 51201818 Roquinimex, a Commodity code, maps to vaccines and immunological agents that state and local health agencies procure — though the single recent opportunity shows a sole source notice for Yellow Fever Vaccine rather than competitive solicitation activity. The Mississippi State Department of Health issued a notice of proposed sole source purchase from Sanofi Pasteur, Inc., with an objection deadline of August 3, 2026 at 10:00 a.m. CST, inviting challenge to the sole source designation from any vendor or entity able to demonstrate alternative supply. The procurement does not specify quantity, contract term, estimated value, or pricing. State health departments appear to be the primary issuing bodies under this code; the scope centers on vaccines required by public health programs.

The code shows minimal recent activity in state and local procurement records. Only one opportunity is present in the available dataset, limiting visibility into geographic spread or issuing-body patterns. The Mississippi State Department of Health contact is Cynthia Brasher, Mississippi State Department of Health Purchasing Department, reachable at Cynthia.brasher@msdh.ms.gov. If Mississippi receives substantiated objections demonstrating alternative vaccine sources, it will withdraw the sole source notice and conduct a competitive bid or selection process; absent such objections, the department must appeal to the Public Procurement Review Board to sustain exclusive-source status.